A recent editorial published in the Annals of Surgical Oncology argues that specialized care networks are no longer optional for rare cancers like mesothelioma. The authors, researchers from the French Network of Rare Peritoneal Cancers (RENAPE), say they are the essential structural response to a decades-long gap between what medicine knows and the treatments that patients actually receive.
Rare Cancers Like Mesothelioma Represent Nearly 25% of All Cancer Deaths
In their editorial, Laurent Villeneuve, Ph.D., Vahan Kepenekian, M.D., Ph.D., and Olivier Glehen, M.D., Ph.D. of RENAPE make the case that the disproportionate death toll from rare cancers like mesothelioma is not primarily caused by the tumors’ biology. Instead, they say, it is a function of how health systems are organized. Rare cancers represent 20 to 22% of all new cancer diagnoses, but they represent nearly 25% of all cancer deaths. The authors say this stems from market failure, fragmented care, and unequal access to expertise rather than from the diseases themselves.
Mesothelioma is cited as a prime example of this problem. Despite its global age-standardized incidence of approximately 0.28 per 100,000 population, roughly 30,000 patients are diagnosed per year worldwide, with mortality nearly matching incidence. While there’s no doubt that these numbers reflect the asbestos-related cancer’s aggressiveness, the authors also point to organizational delays and misdiagnoses that cost patients precious time. A significant number of patients with rare cancers only get their illnesses correctly identified after their initial diagnoses are revised by centralized expert pathology review. In the case of mesothelioma, patients may have multiple consultations, repeated biopsies, and long periods of wasted time before they start receiving the specialized care they need.
For Rare Cancers Like Mesothelioma, Expertise Should Travel
The core principle the authors advance is that expertise in rare cancers like mesothelioma should travel, and the patient shouldn’t have to. By creating hub-and-spoke network architectures in which specialized centers affiliate and share knowledge with autonomous regional and local partners, healthcare preserves proximity for patients while providing the expertise the disease demands. RENAPE established this type of networking structure in 2011, and the group’s internal data show that it reduced the median interval from diagnosis to first oncological treatment by approximately a factor of three, with similar reductions in time to surgery. This represents a dramatic improvement in care that can make a real difference in aggressive diseases like mesothelioma.
The authors also address the research challenge posed by mesothelioma’s rarity. Traditional randomized clinical trials require thousands of patients, but this volume isn’t feasible for rare cancers. This makes international data sharing and collaborative registries essential rather than optional. The authors advocate for population registries with cross-border resolution, FAIR data principles ensuring data is findable, accessible, interoperable, and reusable, and virtual biobanks linking dispersed tissue samples to centralized clinical repositories—infrastructure that allows every mesothelioma case to contribute to collective scientific knowledge. They conclude that this type of networking must be implemented everywhere, in every national cancer plan, and powered by shared data to provide real benefits for every mesothelioma and rare cancer patient.
If you or someone you love has been diagnosed with mesothelioma, the Patient Advocates at Mesothelioma.net are here to make sure you get what you need. Contact us today at 1-800-692-8608 to learn more.
